0000000000776777

AUTHOR

A. Sáenz

showing 2 related works from this author

Low Energy Gamma Ray Imager (LEGRI)

1995

The Low Energy Gamma Ray Imager (LEGRI) will be one of the three instruments carried by the first MINISAT mission. LEGRI aims to demonstrate the technological feasibility of a new generation of low energy gamma-ray telescopes with imaging, medium resolution spectroscopy and high continuum sensitivity in the 20-200 keV spectral region, based on HgI2 solid state detector technology.

Medium resolutionPhysicsOpticsLow energybusiness.industryAstrophysics::High Energy Astrophysical PhenomenaGamma rayAstrophysicsSolid state detectorbusinessSpectroscopyStar sensor
researchProduct

Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gast…

2009

Purpose To determine in a Phase II trial whether preoperative irinotecan–cisplatin (IC) followed by concurrent IC therapy and radiotherapy (IC/RT) improved outcome in patients with resectable, locally advanced gastric adenocarcinoma (GC) or esophagogastric junction cancer (EGJC). Patients and Methods Patients with resectable Stage II–IV, M0 GC or EGJC made up the study population. The primary endpoint was pathologic complete response (pCR). Two courses of IC (irinotecan, 65mg/m 2 ; cisplatin, 30mg/m 2 on Days 1 and 8 every 21 days) were given. Patients without progression then received IC/RT, consisting of daily radiotherapy (45Gy) with concurrent IC (irinotecan, 65mg/m 2 ; cisplatin, 30mg/…

OncologyCancer Researchmedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaNeutropeniaIrinotecanGastroenterologyDrug Administration ScheduleStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studySurvival rateCisplatinChemotherapyRadiationbusiness.industryRemission Inductionmedicine.diseaseCombined Modality TherapySurvival RateRadiation therapyIrinotecanOncologySpainPreoperative PeriodAdenocarcinomaCamptothecinEsophagogastric JunctionCisplatinbusinessAlgorithmsmedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct